Focus on Cellular Biomedicine Group Inc. (NASDAQ:CBMG)

751

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has announced EPS of $(0.43) for its most recent quarter.

The EPS that Cellular Biomedicine Group Inc. has reported for the most recent quarter stemmed from sales of of 57,828%, which grew -9.88% from a year-ago period.

To generate the revenue, Cellular Biomedicine Group Inc. incurred direct expenses amounting to $625,099, being the cost of goods sold or cost of sales. After subtracting the cost of sales from the proceeds, the company ended up with gross profit of $(567,271).

Recently, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced the voting results of its 2017 Annual Meeting of Stockholders, held on April 28, 2017 in Cupertino, California. Approximately 65.7% of the Company’s outstanding shares were represented at the 2017 Annual Meeting.

Let?s look into the technical of the stock

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend. The market is in highly oversold territory. Beware of a trend reversal.

Because the company incurred other expenses in the course of its operations, subtracting those from the gross profit and dividing the difference by the number of shares outstanding yielded the reported revenue of $(0.43). Investors should keep in mind that Cellular Biomedicine Group Inc. exited the latest quarter with diluted shares outstanding amounting to 14.28M.

What is Cellular Biomedicine Group Inc.?s liquidity situation and can it continue funding its operations? The company exited the latest quarter with cash balance of 39.25M%, having generated free cash flow of $(4.83M) during the quarter. Net cash flow from operations during the quarter was $(3.8M), leading to net change in cash of $(4.86M).

What about the health of the company’s balance sheet? Cellular Biomedicine Group Inc. had total assets of $68.63M at the end of the most recent quarter, while total liabilities amounted to $2.73M.

As for the Wall Street sentiment regarding the stock, some 1 analysts have commented on Cellular Biomedicine Group Inc. so far, giving it an average analyst recommendation of Buy. Investors should understand that a recommendation of 1 up to 1.24 indicates the stock is a BUY, which recommendation of 2.75 up to 3.00 signifies a stock is a SELL.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.